SciELO - Scientific Electronic Library Online

 
vol.135 número6Índice de medicina preventiva: Una medida integradora de la cobertura de los programas preventivosInteracción entre genotipo y nutrición: interpretación de estudios epidemiológicos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista médica de Chile

versão impressa ISSN 0034-9887

Resumo

GARCIA B, Leonel; GALVEZ G, Javier  e  ARMENDARIZ B, Juan. Therapeutical targets for revert liver fibrosis. Rev. méd. Chile [online]. 2007, vol.135, n.6, pp.783-791. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872007000600015.

Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others. Efficient and well-tolerated antifibrotic drugs are still lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlight recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged

Palavras-chave : Fatty liver; Fibrosis; Liver cirrhosis.

        · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons